MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
83.88
+0.56
+0.67%
Pre Market: 84.68 +0.8 +0.95% 04:34 02/11 EST
OPEN
83.00
PREV CLOSE
83.32
HIGH
84.90
LOW
82.65
VOLUME
3
TURNOVER
0
52 WEEK HIGH
96.54
52 WEEK LOW
33.70
MARKET CAP
5.24B
P/E (TTM)
132.87
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PTGX last week (0202-0206)?
Weekly Report · 2d ago
Director’s Big Move: Major Insider Stock Sale Shakes Up Protagonist Therapeutics
TipRanks · 4d ago
Protagonist Therapeutics Director William D. Waddill Reports Sale of Common Shares
Reuters · 4d ago
Protagonist Therapeutics Is Maintained at Buy by Jefferies
Dow Jones · 02/02 21:34
Protagonist Therapeutics Price Target Raised to $118.00/Share From $95.00 by Jefferies
Dow Jones · 02/02 21:34
Jefferies Maintains Buy on Protagonist Therapeutics, Raises Price Target to $118
Benzinga · 02/02 21:24
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Sarepta Therapeutics (SRPT) and Protagonist Therapeutics (PTGX)
TipRanks · 02/02 13:10
Weekly Report: what happened at PTGX last week (0126-0130)?
Weekly Report · 02/02 10:17
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.